(Yicai) Nov. 8 -- Edwards Lifesciences will accelerate the introduction of new cardiovascular products into China after the ...

Analysts said the findings complicate the outlook for a U.S. launch of Boston Scientific's aortic valve replacement device.

Fewer rehospitalizations and better functional and QoL outcomes point to TAVI as a good choice, but longer-term data are ...

On Wednesday, Boston Scientific Corporation (NYSE:BSX) released the results of the primary endpoint of the ACURATE IDE trial ...

Transcatheter aortic valve replacement (TAVR) devices continue to make a splash in the world of medical technology, with the Sapien 3 by Edwards Lifesciences Corp. leading the way. Results of the ...

JPMorgan keeps an Overweight rating on Edwards Lifesciences (EW) after the company reported results from the EARLY TAVR trial, the first of its ...